These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37242729)

  • 1. Dose-Ranging Plasma and Genital Tissue Pharmacokinetics and Biodegradation of Ultra-Long-Acting Cabotegravir In Situ Forming Implant.
    Young IC; Thorson AL; Shrivastava R; Sykes C; Schauer AP; Cottrell ML; Kashuba ADM; Benhabbour SR
    Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection.
    Young IC; Massud I; Cottrell ML; Shrivastava R; Maturavongsadit P; Prasher A; Wong-Sam A; Dinh C; Edwards T; Mrotz V; Mitchell J; Seixas JN; Pallerla A; Thorson A; Schauer A; Sykes C; De la Cruz G; Montgomery SA; Kashuba ADM; Heneine W; Dobard CW; Kovarova M; Garcia JV; García-Lerma JG; Benhabbour SR
    Nat Commun; 2023 Feb; 14(1):708. PubMed ID: 36759645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
    Patel P; Teichner P; Elliot E; Boffito M; Murray M; Polli JW; Baker M; Ford SL; Han K; Russu A; Crauwels H; D'Amico RD; Spreen WR; van Wyk J
    Ther Adv Infect Dis; 2023; 10():20499361231214626. PubMed ID: 38107552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting injectable multipurpose prevention technology for prevention of HIV and unplanned pregnancy.
    Young IC; Pallerla A; Cottrell ML; Maturavongsadit P; Prasher A; Shrivastava R; De la Cruz G; Montgomery SA; Schauer A; Sykes C; Kashuba ADM; Benhabbour SR
    J Control Release; 2023 Nov; 363():606-620. PubMed ID: 37797892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
    Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
    Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
    Landovitz RJ; Li S; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; Zhang Y; Tolley E; Sugarman J; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Spreen WR; Cohen MS; McCauley M; Eron JJ
    PLoS Med; 2018 Nov; 15(11):e1002690. PubMed ID: 30408115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis.
    Pons-Faudoa FP; Sizovs A; Di Trani N; Paez-Mayorga J; Bruno G; Rhudy J; Manohar M; Gwenden K; Martini C; Chua CYX; Varchi G; Marzinke MA; Grattoni A
    J Control Release; 2019 Jul; 306():89-96. PubMed ID: 31136811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sexually transmitted infections and depot medroxyprogesterone acetate do not impact protection from simian HIV acquisition by long-acting cabotegravir in macaques.
    Vishwanathan SA; Zhao C; Luthra R; Khalil GK; Morris MM; Dinh C; Gary MJ; Mitchell J; Spreen WR; Pereira LE; Heneine W; García-Lerma JG; McNicholl JM
    AIDS; 2022 Feb; 36(2):169-176. PubMed ID: 34482355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Injection Volume and Route of Administration on Dolutegravir In Situ Forming Implant Pharmacokinetics.
    Joiner JB; King JL; Shrivastava R; Howard SA; Cottrell ML; Kashuba ADM; Dayton PA; Benhabbour SR
    Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35335991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects.
    Ford SL; Lou Y; Lewis N; Kostapanos M; D'Amico R; Spreen W; Patel P
    Antivir Ther; 2019; 24(4):301-308. PubMed ID: 30896438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251.
    Andrews CD; Bernard LS; Poon AY; Mohri H; Gettie N; Spreen WR; Gettie A; Russell-Lodrigue K; Blanchard J; Hong Z; Ho DD; Markowitz M
    AIDS; 2017 Feb; 31(4):461-467. PubMed ID: 27902508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain.
    Moreno S; Rivero A; Ventayol P; Falcó V; Torralba M; Schroeder M; Neches V; Vallejo-Aparicio LA; Mackenzie I; Turner M; Harrison C
    Infect Dis Ther; 2023 Aug; 12(8):2039-2055. PubMed ID: 37452174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis.
    Durham SH; Milam A; Waer D; Chahine EB
    Ann Pharmacother; 2023 Mar; 57(3):306-316. PubMed ID: 35778802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077.
    Blair CS; Li S; Chau G; Cottle L; Richardson P; Marzinke MA; Eshleman SH; Adeyeye A; Rinehart AR; Margolis D; McCauley M; Hendrix CW; Landovitz RJ;
    J Acquir Immune Defic Syndr; 2020 Sep; 85(1):93-97. PubMed ID: 32452972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis.
    Wang W; Zhao S; Wu Y; Duan W; Li S; Li Z; Guo C; Wang W; Zhang T; Wu H; Huang X
    JMIR Public Health Surveill; 2023 Jul; 9():e46767. PubMed ID: 37498645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women.
    Trezza C; Ford SL; Gould E; Lou Y; Huang C; Ritter JM; Buchanan AM; Spreen W; Patel P
    Br J Clin Pharmacol; 2017 Jul; 83(7):1499-1505. PubMed ID: 28087972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Securing accelerated access to long-acting injectable cabotegravir for HIV prevention in low- and middle-income countries.
    Jenkins SY; Resar D; Panos Z; Staple A; Watkins M; Ripin D; Amole C
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26101. PubMed ID: 37439082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
    Marzinke MA; Fogel JM; Wang Z; Piwowar-Manning E; Kofron R; Moser A; Bhandari P; Gollings R; Bushman LR; Weng L; Halvas EK; Mellors J; Anderson PL; Persaud D; Hendrix CW; McCauley M; Rinehart AR; St Clair M; Ford SL; Rooney JF; Adeyeye A; Chariyalertsak S; Mayer K; Arduino RC; Cohen MS; Grinsztejn B; Hanscom B; Landovitz RJ; Eshleman SH
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0005323. PubMed ID: 36995219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabotegravir long-acting for HIV-1 prevention.
    Andrews CD; Heneine W
    Curr Opin HIV AIDS; 2015 Jul; 10(4):258-63. PubMed ID: 26049951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection.
    Radzio-Basu J; Council O; Cong ME; Ruone S; Newton A; Wei X; Mitchell J; Ellis S; Petropoulos CJ; Huang W; Spreen W; Heneine W; García-Lerma JG
    Nat Commun; 2019 May; 10(1):2005. PubMed ID: 31043606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.